olaparib + liposomal doxorubicin

This is a combination regimen of **olaparib**, a potent oral small molecule poly(ADP-ribose) polymerase (PARP) inhibitor, and **liposomal doxorubicin** (specifically, pegylated liposomal doxorubicin, PLD), a formulation of the cytotoxic anthracycline chemotherapeutic **doxorubicin** encapsulated within pegylated liposomes. - **Olaparib** inhibits PARP enzymes, involved in repairing single-strand DNA breaks through the base-excision repair pathway, leading to accumulation of DNA damage and synthetic lethality in tumors with homologous recombination deficiencies (such as BRCA1/2 mutations)[2]. - **Liposomal doxorubicin** works by intercalating into DNA and inhibiting topoisomerase II, preventing DNA replication and leading to cell death[4]. The combination aims to increase antitumor effects through synergistic mechanisms: DNA damage induced by doxorubicin augments the cytotoxic potential of olaparib, particularly in ovarian cancer and other advanced solid tumors with HRD or platinum resistance[2][3]. It has primarily been studied in platinum-resistant or platinum-sensitive ovarian cancer (including patients with and without BRCA mutations) and advanced solid tumors[1][2][3].

Other names

olaparib plus liposomal doxorubicinolaparib combination with pegylated liposomal doxorubicinolaparib + PLDolaparib + pegylated liposomal doxorubicin